Intraocular Lens Postmarket Surveillance Supported By Ophthalmic Panelists
This article was originally published in The Gray Sheet
Executive Summary
Postmarket surveillance for phakic intraocular lenses (IOLs) is largely favored by members of FDA's Ophthalmic Devices Panel, although recommended duration could vary depending on risk
You may also be interested in...
Separate Phakic IOL Trials Recommended For Young, Old Patients
Refractive implant manufacturers pursuing claims for device implantation in phakic eyes - those with a natural lens - should conduct separate studies on younger and older patient populations to examine the risk of cataractogenesis, FDA's Ophthalmic Devices Advisory Panel recommended at a May 12 meeting.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.